EcoDrugPlus

Dihydropyridine-Sensitive L-Type Skeletal Muscle Calcium Channel Subunit Alpha-1-Like

Ensembl ID : ENSMAMG00000023687
Gene Symbol: LOC113130179
2 Cross references
192 Possible Orthologues:

Dihydropyridine-Sensitive L-Type Skeletal Muscle Calcium Channel Subunit Alpha-1-Like

Ensembl ID : ENSMAMG00000006070
Gene Symbol: LOC113145940
2 Cross references
199 Possible Orthologues:

Dihydropyrimidine Dehydrogenase B

Ensembl ID : ENSMAMG00000011621
Gene Symbol: DPYDB
2 Cross references
211 Possible Orthologues:

Discoidin Domain Receptor Tyrosine Kinase 2a

Ensembl ID : ENSMAMG00000018316
Gene Symbol: DDR2A
2 Cross references
204 Possible Orthologues:

Discoidin Domain-Containing Receptor 2-Like

Ensembl ID : ENSMAMG00000001656
Gene Symbol: LOC113134148
2 Cross references
190 Possible Orthologues:

Dopamine Receptor D1b

Ensembl ID : ENSMAMG00000021363
Gene Symbol: DRD1B
3 Cross references
198 Possible Orthologues:

Dopamine Receptor D2a

Ensembl ID : ENSMAMG00000010140
Gene Symbol: DRD2A
3 Cross references
208 Possible Orthologues:

Dopamine Receptor D3

Ensembl ID : ENSMAMG00000001639
Gene Symbol: DRD3
3 Cross references
203 Possible Orthologues:

Dopamine Receptor D4

Ensembl ID : ENSMAMG00000022858
Gene Symbol: DRD4
2 Cross references
165 Possible Orthologues:

Egl-9 Family Hypoxia Inducible Factor 1

Ensembl ID : ENSMAMG00000016947
Gene Symbol: EGLN1
3 Cross references
220 Possible Orthologues:

Egl-9 Family Hypoxia-Inducible Factor 2

Ensembl ID : ENSMAMG00000010817
Gene Symbol: EGLN2
2 Cross references
191 Possible Orthologues:

Egl-9 Family Hypoxia-Inducible Factor 3

Ensembl ID : ENSMAMG00000000031
Gene Symbol: EGLN3
3 Cross references
197 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).